Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

Bence, 2001, Impairment of the ubiquitin-proteasome system by protein aggregation, Science, 292, 1552, 10.1126/science.292.5521.1552 Berns, 2004, A large-scale RNAi screen in human cells identifies new components of the p53 pathway, Nature, 428, 431, 10.1038/nature02371 Bolden, 2006, Anticancer activities of histone deacetylase inhibitors, Nat. Rev. Drug Discov., 5, 769, 10.1038/nrd2133 Carey, 2006, Histone deacetylase inhibitors: gathering pace, Curr. Opin. Pharmacol., 6, 369, 10.1016/j.coph.2006.03.010 Chan, 2001, p300/CBP proteins: HATs for transcriptional bridges and scaffolds, J. Cell Sci., 114, 2363, 10.1242/jcs.114.13.2363 Chen, 2002, Rad23 promotes the targeting of proteolytic substrates to the proteasome, Mol. Cell. Biol., 22, 4902, 10.1128/MCB.22.13.4902-4913.2002 Chen, 2001, Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly, EMBO Rep., 2, 933, 10.1093/embo-reports/kve203 Duvic, 2006, Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma, Br. J. Cancer, 95, S13, 10.1038/sj.bjc.6603465 Fujiwara, 2004, Structure of the ubiquitin-interacting motif of S5a bound to the ubiquitin-like domain of HR23B, J. Biol. Chem., 279, 4760, 10.1074/jbc.M309448200 Gilon, 1998, Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae, EMBO J., 17, 2759, 10.1093/emboj/17.10.2759 Hiyama, 1999, Interaction of hHR23 with S5a. The ubiquitin-like domain of hHR23 mediates interaction with S5a subunit of 26 S proteasome, J. Biol. Chem., 274, 28019, 10.1074/jbc.274.39.28019 Inche, 2006, Chromatin control and cancer-drug discovery: realizing the promise, Drug Discov. Today, 11, 97, 10.1016/S1359-6446(05)03691-3 Khan, 2008, Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas, Nat. Clin. Pract. Oncol., 5, 714, 10.1038/ncponc1238 Li, 1993, Characterization of molecular defects in xeroderma pigmentosum group C, Nat. Genet., 5, 413, 10.1038/ng1293-413 Mann, 2007, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist, 12, 1247, 10.1634/theoncologist.12-10-1247 Marks, 2005, Histone deacetylase inhibitors in programmed cell death and cancer therapy, Cell Cycle, 4, 549, 10.4161/cc.4.4.1564 Marks, 2007, Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug, Nat. Biotechnol., 25, 84, 10.1038/nbt1272 Minucci, 2006, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat. Rev. Cancer, 6, 38, 10.1038/nrc1779 Nalepa, 2006, Drug discovery in the ubiquitin-proteasome system, Nat. Rev. Drug Discov., 5, 596, 10.1038/nrd2056 Ng, 2002, Developmental defects and male sterility in mice lacking the ubiquitin-like DNA repair gene mHR23B, Mol. Cell. Biol., 22, 1233, 10.1128/MCB.22.4.1233-1245.2002 Richardson, 2006, Bortezomib: proteasome inhibition as an effective anticancer therapy, Annu. Rev. Med., 57, 33, 10.1146/annurev.med.57.042905.122625 Richon, 2006, Cancer biology: mechanism of antitumour action of vorinostat (suberolyanilide hydroxamic acid), a novel deacetylase inhibitor, Br. J. Cancer, 95, S2, 10.1038/sj.bjc.6603463 Schauber, 1998, Rad23 links DNA repair to the ubiquitin/proteasome pathway, Nature, 391, 715, 10.1038/35661 Sugasawa, 1997, Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity, Mol. Cell. Biol., 17, 6924, 10.1128/MCB.17.12.6924 Wilkinson, 2001, Proteins containing the UBA domain are able to bind to multi-ubiquitin chains, Nat. Cell Biol., 3, 939, 10.1038/ncb1001-939 Xu, 2007, Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, 26, 5541, 10.1038/sj.onc.1210620